Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cholestatic liver diseases].

R Thimme1, O G Opitz, H E Blum

  • 1Medizinische Universitätsklinik Freiburg, Abteilung Innere Medizin II.

Therapeutische Umschau. Revue Therapeutique
|October 2, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spatial immune profiling complements genomic sequencing in biliary tract cancer: hypothesis-generating use cases.

ESMO gastrointestinal oncology·2026
Same author

Frequent high-level rifaximin resistance in <i>Escherichia coli</i> associated with long-term treatment of patients with liver cirrhosis: a prospective, controlled study.

Microbiology spectrum·2025
Same author

The German Network for Personalized Medicine to enhance patient care and translational research.

Nature medicine·2023
Same author

[Correction: Colorectal carcinoma].

Deutsche medizinische Wochenschrift (1946)·2022
Same author

High-dimensional profiling reveals Tc17 cell enrichment in active Crohn's disease and identifies a potentially targetable signature.

Nature communications·2022
Same author

[Colorectal carcinoma].

Deutsche medizinische Wochenschrift (1946)·2021
Same journal

[Multimodal Cardiac Imaging: New Developments for Clinical Practice].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Coronary angiography: From cardiac catheterization to advanced interventional cardiovascular imaging].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Athlete's heart: role of cardiac imaging in the prevention of sudden cardiac death].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Multimodal imaging in cardiac amyloidosis and cardiac sarcoidosis].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Inflammatory Heart Disease: The Role of Multimodality Cardiac Imaging in Myocarditis and Pericarditis].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

State-of-the-Art Cardiac Imaging

Therapeutische Umschau. Revue therapeutique·2026
See all related articles

Primary biliary cirrhosis and primary sclerosing cholangitis are autoimmune liver diseases. Ursodeoxycholic acid is a key therapy, with immunosuppression or liver transplantation for advanced cases.

Area of Science:

  • Hepatology
  • Autoimmune Diseases
  • Gastroenterology

Background:

  • Primary biliary cirrhosis (PBC), autoimmune cholangitis (AIC), and primary sclerosing cholangitis (PSC) are distinct autoimmune cholestatic liver diseases.
  • Overlap syndromes present with features of both cholestatic liver disease and autoimmune hepatitis.
  • These conditions share histological findings of bile duct lesions and can progress to cirrhosis.

Purpose of the Study:

  • To outline the characteristics and therapeutic approaches for autoimmune cholestatic liver diseases.
  • To differentiate between PBC, AIC, and PSC.
  • To describe management strategies including medical therapy and surgical interventions.

Main Methods:

  • Review of clinical presentations, diagnostic markers (e.g., anti-mitochondrial antibodies, P-ANCA), and histological findings.

Related Experiment Videos

  • Description of established and recommended treatments, including ursodeoxycholic acid (UDC) and immunosuppression.
  • Discussion of complications and advanced treatment options like liver transplantation.

    • Main Results:

    • PBC is characterized by elevated alkaline phosphatase and gamma-glutamyl transferase, with anti-mitochondrial antibodies being typical.
    • PSC is frequently associated with inflammatory bowel diseases and P-ANCA, with characteristic bile duct lesions on cholangiography.
    • Ursodeoxycholic acid (UDC) is the primary therapy for slowing disease progression in early stages.

    Conclusions:

    • Autoimmune cholestatic liver diseases require specific diagnostic criteria and tailored treatment strategies.
    • Early intervention with UDC can halt disease progression in PBC and PSC.
    • Immunosuppression and liver transplantation are crucial for managing non-responders and advanced stages of PBC and PSC.